Lesson plan

Nitromemantine

Nitromemantine (developmental code names YQW-36 and EM-036), also known as NitroSynapsin, is a derivative of memantine developed in 2006 for the treatment of Alzheimer's disease. It has been shown to reduce excitotoxicity mediated by over-activation of the glutamatergic system, by blocking NMDA receptors. It was being developed for treatment of Alzheimer's disease and pervasive developmental disorders like autism, but development was discontinued in 2023.

Back to article

Article summary

Nitromemantine (developmental code names YQW-36 and EM-036), also known as NitroSynapsin, is a derivative of memantine developed in 2006 for the treatment of Alzheimer's disease. It has been shown to reduce excitotoxicity mediated by over-activation of the glutamatergic system, by blocking NMDA receptors. It was being developed for treatment of Alzheimer's disease and pervasive developmental disorders like autism, but development was discontinued in 2023.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.